Back to Journals » Open Access Journal of Contraception » Volume 5

Contraceptive implants: current perspectives

Authors Rowlands S, Searle S

Received 12 March 2014

Accepted for publication 6 April 2014

Published 23 September 2014 Volume 2014:5 Pages 73—84

DOI https://doi.org/10.2147/OAJC.S55968

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Sam Rowlands,1,2 Stephen Searle3

1Centre of Postgraduate Medical Research and Education, School of Health and Social Care, Bournemouth University, Bournemouth, United Kingdom; 2Dorset HealthCare, Bournemouth, United Kingdom; 3Sexual Health Services, Chesterfield, United Kingdom

Abstract: Progestin-only contraceptive implants are a highly cost-effective form of long-acting reversible contraception. They are the most effective reversible contraceptives and are of a similar effectiveness to sterilization. Pregnancies are rare in women using this method of contraception, and those that do occur must be fully investigated, with an ultrasound scan of the arm and serum etonogestrel level if the implant cannot be located. There are very few contraindications to use of implants, and they have an excellent safety profile. Both acceptability and continuation with the method are high. Noncontraceptive benefits include improvements in dysmenorrhea, ovulatory pain, and endometriosis. Problematic bleeding is a relatively common adverse effect that must be covered in preinsertion information-giving and supported adequately if it occurs. Recognized training for both insertion and removal should be undertaken. Care needs to be taken at both insertion and removal to avoid neurovascular injury. Implants should always be palpable; if they are not, noninsertion should be assumed until disproven. Etonogestrel implants are now radiopaque, which aids localization. Anticipated difficult removals should be performed by specially trained experts.

Keywords: contraceptive, subdermal implant, etonogestrel, levonorgestrel, progestin-only, long-acting reversible contraception

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Readers of this article also read:

Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers

Kim YH, Choi HY, Lim HS, Lee SH, Jeon HS, Hong D, Kim SS, Choi YK, Bae KS

Drug Design, Development and Therapy 2015, 9:1419-1426

Published Date: 10 March 2015

Topical difluprednate for the treatment of Harada’s disease

Onishi SM, Asahi MG, Chou C, Gallemore RP

Clinical Ophthalmology 2015, 9:157-167

Published Date: 21 January 2015

PDLA a potential new potent topical analgesic: a case report

Goldberg JS

Local and Regional Anesthesia 2014, 7:59-61

Published Date: 24 October 2014

Synthesis, pharmacokinetics, and biological use of lysine-modified single-walled carbon nanotubes

Mulvey JJ, Feinberg EN, Alidori S, McDevitt MR, Heller DA, Scheinberg DA

International Journal of Nanomedicine 2014, 9:4245-4255

Published Date: 4 September 2014

Non-adherence to topical treatments for actinic keratosis

Shergill B, Zokaie S, Carr AJ

Patient Preference and Adherence 2014, 8:35-41

Published Date: 17 December 2013

Erratum

Schuelert N, Russell FA, McDougall JJ

Orthopedic Research and Reviews 2011, 3:9-10

Published Date: 1 March 2011